Atlas Trials

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

Clinical trial NCT01980628 · COMPLETED

Trial details

NCT number
NCT01980628
Sponsor
Pharmacyclics LLC.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Marginal Zone LymphomaB-cell Lymphoma
Start date
2013-12-01
Primary completion
2016-07-01
Enrollment
63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.